Phase I study of combination chemotherapy with erlotinib and S-1 as the 2nd or 3rd-line treatment in platinum-refractory advanced non-small cell lung cancer (TORG0808).
Phase of Trial: Phase I
Latest Information Update: 13 May 2016
At a glance
- Drugs Erlotinib (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 09 Nov 2011 New trial record